Research - TCH - Medical Oncology - Research presentations

Research presentations

Yip D, Karapetis CS, Strickland A, Lang G, Holford C, Harper PG. A Phase I trial of escalating dose eniluracil/oral 5-fluorouracil plus oxaliplatin (OXA) in patients with advanced gastrointestinal malignancies. Proc Clin Onc Soc Austr Annual Scientific Meeting 2000; Abstract142,(Presentation).

Yip D, Karapetis CS, Strickland A, Steer C, Holford C, Harper PG. A Phase I trial of escalating dose eniluracil/oral 5-fluorouracil plus oxaliplatin (OXA) in patients with advanced gastrointestinal malignancies. Proc Am Soc Clin Oncol 2001; Abstract 2079.

Donellan P, Strickland AH, Steer, Yip D, Ring A, Mason R, Owen W, Ellul F, Dussek R, Harper PG. Downstaging chemotherapy followed by surgery in the treatment of locally advanced oesophagogastric cancer. British Oesophagogastric Cancer Group Meeting, London, 2001 (Oral presentation)

Strickland A, Donellan P, Yip D, Steer C, Ring A, Marx G, Mason R, Harper P. Downstaging chemotherapy followed by surgery in the treatment of locally advanced oesophagogastric cancer. Medical Oncology Group of Australia Annual Scientific Meeting, Sunshine Coast, 2001 (Poster).

Hawkins CA, Yip D, Bowden F,Hurwitz M, Cook MC. Common variable immunodeficiency in an 88 year old woman. Proc Aust Soc Clin Immuno Allerg Annual Scientific Meeting 2001; (Presentation).

Karapetis CS, Steer C, Strickland AH, Yip D, Marx G, Yip S, Harper PG. A phase I/II study of epirubicin, cisplatin, high dose 24-hour infusion 5 fluorouracil and sodium folinate (ECSF) for advanced gastroesophageal carcinoma. Proc Am Soc Clin Oncol 2002; 21 A2245.

Gorddard N, Shadbolt B. Craft P. Describing the onset of weakness in patients with advanced cancer. Proc Am Soc Clin Oncol 2002; 21 A1500 (Poster).

Barresi J, Byrne D, Shadbolt B, Stuart-Harris R. The Canberra symptom scorecard: a tool to measure symptoms in patients with metastatic cancer. Proc Am Soc Clin Oncol 2002; 21 A994 (Presentation).

Hughes B, Nahar N, Chao M, Carroll S, Goldstein D, Yip D. An Audit of the toxicity of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma. Proc Medical Oncology Group National Conference, Canberra 2003 (Presentation)

Lim L, Gibbs P, Smith D, Yip D, Little A, Bailey W, Shapiro JD, Dowling R, Lichtenstein M. Prospective study of selective internal radiation therapy with intra-arterial infusion of yttrium 90 microspheres (Sirtex) for non-resectable primary or secondary hepatic malignancies. Proc Medical Oncology Group National Conference, Canberra 2003 (Poster and Presentation).

Gorddard N, Hughs B, May J, Yip D, Craft P, Leong D, Stuart-Harris R. A phase II study of vinorelbine and ifosphamide for previously untreated advanced non-small cell lung cancer. Proc Clinical Oncological Society of Australia, Perth 2003 (Poster).

Lim L, Gibbs P, Smith D, Yip D, Bailey W, Shapiro JD, Dowling R, Lichtenstein M, Little A. Prospective study of selective internal radiation therapy (SIR spheres) in patients with metastatic colorectal cancer previously treated with 5-fluorouracil. ASCO Gastrointestinal Symposium, San Francisco 2004 (Poster).

Cheong KA, Karapetis C, Chrystal KF, Yip D, Strickland A, Steer C, Harper P. A phase I/II study of epirubicin, cisplatin, high dose 24hour infusion 5 fluorouracil and sodium folinate (ECSF) for advanced gastroesophageal carcinoma. ASCO Gastrointestinal Symposium, San Francisco, 2004 (Abstract 69)

Hughes B, Nahar N, Yip D, Chao M, Carroll S, Goldstein D, Gibbs P, Burmeister B, Karapetis C. An Audit of the toxicity of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience.15th International Congress on Anti-Cancer Treatment, Paris 2004 (Poster)

Grimpen, F, Yip D, McArthur G, Waring P, Goldstein D, Loughrey, Chong, G. Resistance to imatinib mesylate associated with absence of FDG-avidity on PET and acquired exon 17 mutation in gastrointestinal stromal tumour (GIST). Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Presentation).

Yip D, Strangman D, McNally E,The Establishment of a Cancer Resources Centre and Carers Lounge. Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Poster).

Lim L, Gibbs P, Smith D, Yip D, Dowling R, Lichtenstein M, Little A, Bailey W, Shapiro JD. Prospective study of selective internal radiation therapy (SIR spheres) in patients with metastatic colorectal cancer. Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Poster).

Dahlstrom JE, Craft P, Zhang Y, Buckingham J, Jacob G, Tait N. Breast cancer and treatment in the Australian Capital Territory (ACT) and South Eastern New South Wales (SE NSW) Quality Assurance Project 1997-2002. Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Poster).

Lewis C, Yip D, Zingarelli G. Anticipated Changes to Antiemetic Presecribing Practice in Chemotherapy Patients Involved in a Special Access Scheme for Aprepitant: A Neurokinin-1 (NK-1) Receptor Antagonist. Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Poster).

Pranavan G, Northey J, Kuhnell C, Boland M, Yip D. The efficacy and tolerability of the Penguin Scalp Cooling System (SCS) for prevention of chemotherapy induced alopecia at The Canberra Hospital. Clinical Oncological Society of Australia Annual Scientific Meeting, Brisbane 2005 (Poster).

Davis AJ, Lewis CR, Moylan EJ, Parnis FX, Brew S, Ackland SP. A phase II multicenter study of combination chemotherapy with capecitabine (C) and intravenous (iv) vinorelbine (V) in patients (pts) with pretreated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006; 24 A10665.

Gibbs, P, Tan T.H.,Yip, D, Kosmider S. Clinical Experience of Selective Internal Radiation Therapy in Combination with Systemic Chemotherapy as First-Line Therapy in Patients with Unresectable Hepatic Metastases from Colorectal Cancer. KL International Breast and Colorectal Cancer Congress, Kuala Lumpur, 2007.

Pranavan G, Gorddard N. Postoperative Chemoradiation for Glioblastoma Multiforme, a retrospective review. Medical Oncology Group Annual Scientific Meeting, Melbourne 2007 (Poster).

Pranavan G, Tan TH, Stuart-Harris R.Clinical Efficacy and Tolerability of Fulvestrant as Third Line Therapy of Metastatic Breast Cancer: A Retrospective Analysis. Proc Clinical Oncological Society of Australia Annual Scientific Meeting, 2007 (Poster).

Tan HT, Kosmider S, Yip D, Gibbs P. Clinical experience of Selective Internal Radiotherapy in combination with chemotherapy as first line therapy in patients with unresectable hepatic metastases from colorectal cancer.Clinical Oncological Society of Australia Annual Scientific Meeting, Adelaide 2007 (Poster).

Stuart-Harris R, Shadbolt B, Chaudri Ross HA. The prognostic significance of discordant receptor results and the progesterone receptor in metastatic breast cancer. Proc European Breast Cancer Conference, Berlin, 2008.

O'Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Zalcberg JR, Trudeau M, Yip D, Vachan B, D Jonker DJ. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17.Proc Am Soc Clin Oncol 2008;26 A4130(Poster).

Tan HT, Kosmider S, Yip D, Gibbs P. Clinical experience of Selective Internal Radiotherapy in combination with chemotherapy as first line therapy in patients with unresectable hepatic metastases from colorectal cancer.Proc Am Soc Clin Oncol, 2008;26, A15080.

Hoy J, Neeman T, Stuart-Harris R, Davis A. Risk of venous thromboembolism in patients receiving FEC chemotherapy for early breast cancer. Clinical Oncological Society of Australia Annual Scientific Meeting 2008(Poster).

Parker S, Skeels A, Yip D. Chemotherapy usage in breast, colorectal cancer and lung cancer patients referred to palliative care in the last months of life. Clinical Oncological Society of Australia Annual Scientific Meeting, Sydney 2008 (Poster)

Tebbutt NC, Gebski V, Wilson K, Cummins M, Chua Y, Robinson B, Broad A, Cunningham D, Simes J, Price T. International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. Proc Am Soc Clin Oncol 2009 27: 4023 (Poster)

Craft PS, Buckingham J, Dahlstrom JE, Beckmann K,Zhang Y, Stuart-Harris R, Jacob G, Roder D, Tait N.Variations in care for operable breast cancer and outcomes between rural and metropolitan centers in Australia.Proc Am Soc Clin Oncol 2009;abstr e11517

Shah B, Kleiven H, Yip D, Gorddard N. Patient-initiated Outpatient Management of Low-risk Febrile Neutropenia. Medical Oncology Group Annual Scientific Meeting, Canberra, 2009 (Poster).

Shah B, Kleiven H, Yip D, Gorddard N. Patient-initiated Outpatient Management of Low-risk Febrile Neutropenia. Clinical Oncological Society of Australia Annual Scientific Meeting, Gold Coast, 2009 (Poster).

Krishnamoorthy Yip D. Bisphosphonate usage in oncology patients and its relationship to osteonecrosis of the jaw: an audit of treatment in an oncology unit. Clinical Oncological Society of Australia Annual Scientific Meeting, Gold Coast, 2009 (Poster).

Goldstein D,Lee C,Hui Y,Shah B,Yip D,McArthur GA. Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib.Proc Am Soc Clin Oncol, 2010 28:7s (Poster).

Kosmider S, Yip D, Tan H, Dowling R, Lichtenstien M, Gibbs P. Selective internal radiation therapy combined with systemic chemotherapy as a first-line treatment for unresectable liver-dominant colorectal cancer. World Congress on Gastrointestinal Cancer, Barcelona Ann Oncol (2010) 21(suppl 6): vi67 (Poster).

Joshi S, Steer CB, Yoong J, Lakhanpal R, Kirsop S, Dunlop T, Mileshkin L, Yip D, Marx GM, Hovey EJ, Della Fiorentina S, Venkateswaran L, Lethborg C, Tattersall Liew MS, Ansell K, Field K, Singal N, Goldstein D. Geriatric assessment (GA) of older patients with cancer in Australia – a multicentre audit. Clinical Oncological Society of Australia Annual Scientific Meeting, Melbourne 2010 (Poster)

Behm C, Li JR, Zhang Y, Dahlstrom JE, Craft PS, Buckingham JM, Rezo A, Stuart-Harris R, Cho C. Female breast cancer in the Australian Capital Territory (ACT): A review of new research. Royal Australasian College of Pathologists, Annual Scientific Meeting, 2011.

Cooper A, Tejani N, Rezo, A, Yip D. Numb Chin Syndrome: A case series of a potentially overlooked but important clinical syndrome associated with malignancy. Clinical Oncological Society of Australia Annual Scientific Meeting, Perth 2011 Abstract 202 (Poster)

Tazbirkova A, Allen R, Kosmider S, Gibbs P, Yip D. Serious hepatic complications of radioactive yttrium microspheres (SIR-Sphere) embolisation of liver tumours. Clinical Oncological Society of Australia Annual Scientific Meeting, Perth 2011 Abstract 216 (Poster).

Butow PN, Phillips F, White K, Underhill C, Grimison P, Yip D, Goldstein D. Improving the Cancer Journey in Rural and Regional Australia. Clinical Oncological Society of Australia Annual Scientific Meeting, Perth 2011 Abstract 387.

Rapke T, De Souza P, Marx G, Parente P, Hill A, Bonaventura A, Michele T, Craft P, Abdi E, Lloyd A Modafinil for fatigue associated with docetaxel-based chemotherapy: a randomized controlled trial. American Society of Clinical Oncology Genitourinary Meeting, 2012.

Malik L, Chua YJ, Butt N, Yip D. Single institutional series of neuroendocrine tumours managed in the Australian Capital Territory. European Neuroendocrine Tumor Society Annual Conference Conference, Copenhagen, 2012.

Ransom D, Wilson D, Bishnoi SK, Simes J, Yip D, Christos Stelios Karapetis CS, Gebski V, Gordon S, Fournier M, Ferry DR, Abbas H, Midgley RA, Price TJ. Results of Australasian Gastrointestinal Trials Group (AGITG) Arctic study: An international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines (FP). Proceedings of the American Society of Clinical Oncology 2012 (Abstract 13007)

Malik L, Chua YJ, Butt N, Yip D. Single institutional series of neuroendocrine tumours managed in the Australian capital territory. Proceedings of the American Society of Clinical Oncology 2012 (Abstract 14703)

Hovey E, De Souza PL, Marx GM, Rapke T, Parente P, Hill A, Bonventura A Michele A, Craft PS, Ehtesham A, Lloyd AR. Modafinil for fatigue associated with docetaxel-based chemotherapy: a randomized controlled trial. Proceedings of the American Society of Clinical Oncology 2012 (Abstract 15152)

Field K, Kosmider S, McKendrick J, Yip D, Parakh S, Burge M, Moore K, Shapiro J, Nott L, Wuttke M, Parente P, Bae S, Gibbs P. Prescribing patterns for bevacizumab in first-line metastatic colorectal cancer: Exploring the introduction of a new drug into routine clinical practice. Medical Oncology Group of Australia Annual Scientific Meeting, Brisbane 2012 (Poster).

Field K, Shapiro J, Yip D, Otty Z, Burge M, Sharma A, Lim L, Lipton L, Stefanou G, Desai J, Tie J, Gibbs P Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A review of routine practice. Medical Oncology Group of Australia Annual Scientific Meeting, Brisbane 2012 (Poster).

Parakh S, Gananahda S, Allen R, Yip D. Cholecystitis as a complication of hepatic implantation of radioactive yttrium resin microspheres for metastatic cancer. Medical Oncology Group of Australia Annual Scientific Meeting, Brisbane 2012 (Poster).

Yip D, Bean EG, Rezo A, Cho C, Zhang Y, Twin J, Carpenter JE, Dahlstrom JE. Breast Cancer Tissue Banking Project in the Australian Capital Territory
Canberra Health Annual Research Meeting 2012 (Poster).

Parakh S, Gananahda S, Allen R, Yip D. Cholecystitis as a complication of hepatic implantation of radioactive yttrium resin microspheres for metastatic cancer. Canberra Health Annual Research Meeting 2012 (Poster).

Yip D, Parakh S, Hemmings C, Kosmider S Filling the knowledge void-the BioGrid facilitated solution. Canberra Health Annual Research Meeting 2012 (Poster).

Price T, Wilson K, Simes J, Yip D, Tebbutt N, Karapetis C, Gebski V, Fournier M, Ferry D, Ransom D. Final results of Australasian Gastro-Intestinal Trials Group (AGITG) ARCTIC Study – An international audit of raltitrexed for patients with cardiac toxicity (CT) induced by Fluoropyrimidines (FP). European Society of Medical Oncology Congress Vienna, 2012.

Ransom D, Wilson K, Simes J, Yip D, Tebbutt N, Karepetic C, Fournier M, Ferry D. Price T. Final results of Australasian Gastrointestinal Trials Group (AGITG) ARTIC Study-An international audit of raltitrexed for patients with cardiac toxicity (CT) induced by fluropyrimidines (FP). Clinical Oncological Society of Australia Annual Scientific Meeting, Brisbane 2012 (Poster)

Vien T, Yip D. A retrospective clinical audit comparing neuropathy associated with two different schedules of oxaliplatin in the treatment of metastastic colorectal carcinoma. Clinical Oncological Society of Australia Annual Scientific Meeting, Brisbane 2012 (Poster)

Wong HL, Field KM, Tie J, Kosmider S, Shapiro JD, McKendrick JJ, Parente P, Lipton LR, Yip D, Parakh S, Nott LM, Gibbs P. Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status? (Poster) Gastrointestinal Cancers Symposium J Clin Oncol 30: 2012 (suppl 34; abstr 534)

Field KM, McKendrick JJ, Shapiro JD, Tie J, Bae S, Burge ME, Yip D, Nott LM, Gibbs P. First-line clinical trials and metastatic colorectal cancer: How selected are clinical trial participants? (Poster) Gastrointestinal Cancers Symposium J Clin Oncol 30: 2012 (suppl 34; abstr 524).

Field KM, Shapiro JD, McKendrick JJ, Hui-Li Wong HL, Desai J, Lipton LR, Suzanne Kosmider, Nott LM, Stefanou G, Parente P, Zimet AS, Lim L, Jennens R, Yip D, Burge ME, Gibbs P. Metastatic colorectal cancer and management in public versus private hospitals: Similarities and differences. (Poster) Gastrointestinal Cancers Symposium J Clin Oncol 30: 2012 (suppl 34; abstr 497).

Lakhanpal R, Stuart-Harris R, Chan A Kotasek D, Beith JM, Cuff K, Bastick PA, Lee CI. A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer. Proceedings of the American Society of Clinical Oncology 2013 (abstr 1079)(Poster)

Parakh S, Ali S, Wong HL, Field KM, Shapiro JD,Nott LM, McKendrick JJ, Gibbs P, Yip D. Patterns of care of elderly patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology 2013 (abstr e14640).

Wong HL, Field KM, Tie J, Kosmider S, Shapiro JD, McKendrick J, Parente P, Lipton LR,Yip D, Parakh S, Nott LM, Gibbs P. Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status? Proceedings of the American Society of Clinical Oncology 2013 (abstr e14583).

Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. Proceedings of the American Society of Clinical Oncology 2013 (abstr 3528)(Poster)

Parakh S, Ali S, Wong HL, Field KM, Shapiro JD,Nott LM, McKendrick JJ,Gibbs P, Yip D. Patterns of care of elderly patients with metastatic colorectal cancer. Canberra Health Annual Research Meeting 2013 (Poster).

Kuo J, Hawkins C, Yip D. Protocol and treatment outcome of rapid desensitization of chemotherapeutic agents in the Capital Region Cancer Service. Canberra Health Annual Research Meeting 2013 (Oral presentation).

Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (rightsided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. Canadian Cancer Research Conference 2013 (Poster).

Kuo J, Hawkins C, Yip D. Treatment outcomes of rapid desensitisation of chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Oral presentation).

Parakh S, Ali S, Wong HL, Field KM, Shapiro JD,Nott LM, McKendrick JJ, Gibbs P, Yip D. Patterns of care of elderly patients with metastatic colorectal cancer. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Oral presentation).

Mizrahi D, Naumann F, Broderick C, Yip D, Davis A, Samara J, Ryan M, Friedlander M. Physical activity (PA) participating for women with ovarian cancer. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Poster presentation).

Curry G, Kuo J, Pranavan G, Yip D. Incidence of gastrointestinal toxicity with capecitabine monotherapy in metastatic breast and metastatic colorectal cancer patients. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Poster presentation).

Kanjanapan Y, Chei-Hussein M, Hemmings C, Yip D. Retrospective analysis of resected gastrointestinal stromal tumours (GISTs) comparing existing risk stratification models and assessing the influence of GIST genotypes on recurrence and mortality. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Poster presentation).

Lee CK, Joensuu H, McArthur G, Montemurro M, Yip D, Goldstein D, Bylina E, Andrzejuk J, Siedlecki JA, Rutkowski P. Development and validation of prognostic nomograms to predict survival outcomes in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first line imatinib therapy. Connective Tissue Oncology Society 18th Annual Meeting; 30 Oct–2 Nov 2013; New York.

Roohullah A, Hui-li Wong HL, Sjoquist K, Field K, Tran B, Shapiro J, McKendrick J, Yip D, Nott L, Gibbs P, Chantrill L. Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the TRACC database. Gastrointestinal Cancers Symposium 2014 (abstract 595) (poster presentation).

Nagrial AM, Chin VT, Sjoquist K, Chantrill LA, Yip D. Survival benefit of second-line chemotherapy in advanced pancreatic adocarcinoma: A systematic review of the literature. Gastrointestinal Cancers Symposium 2014 (abstract 296) (poster presentation)

Lomax A, Wong HL, Field KM, Harold M, Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer. Proceedings of the American Society of Clinical Oncology 2014 (e14518).

Wong HL, Field KM, Lomax A, Tacey M, David Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Tie J, Kosmider S, Parente P, LLim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC) Proceedings of the American Society of Clinical Oncology 2014 (e14558).

Wong HL, Field KM, Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Lipton LR, Stefanou G, Tie J, Kosmider S, Parente P, Wong R, Lim L, Cooray P, Tran B, Desai J, Gibbs P. Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care. Proceedings of the American Society of Clinical Oncology 2014 (e17637).

Tie J, Kinde I, Wang Y, Wong HL, Skinner I, Wong R, Steel M, Diaz LA, Papadopoulos N, Kosmider S, Yip D, Underhill C, Haydon AM, Christie M, Strausberg R, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). Proceedings of the American Society of Clinical Oncology 2014 (abstract 11015) (poster presentation).

Chin VT, Nagrial A, Chantrill LA, Sjoquist KM, O'Connor C, Pajic M, ABiankin AV, Yip D. Targeted therapies in the treatment of advanced pancreatic adenocarcinoma (PC): A systematic review and meta-analysis of randomized trials. Proceedings of the American Society of Clinical Oncology 2014 (abstract 15209).

Kanjanapan Y, Dai D, Kwan E, Lawrentschuk N, Andrews M, Davis I, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P, Tran B, Yip D. Sunitinib therapy for metastatic renal cell carcinoma (mRCC) in elderly patients (age 70 and over): a multi-institutional Australian experience. Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Annual Scientific Meeting, Melbourne 2014 (Poster presentation).

Dai D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Andrews M, Davis I, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P,Tran B. Real world data regarding patterns of care in Australian patients with metastatic renal cell carcinoma (mRCC). Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Annual Scientific Meeting, Melbourne 2014 (Poster presentation).

Chin V, Nagrial A, Chantrill L, Sjoquist K, O’Connor C, Pajic M, Biankin A, Yip D. Pharmacologic interventions for advanced pancreatic cancer (PC) – a meta-analysis comparing gemcitabine alone (G) versus gemcitabine combinations (GCS). Medical Oncology Group of Australia Annual Scientific Meeting 2014 (oral presention).

Lomax A, Wong HL, Field KM, Harold M, Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Prognostic impact of clinicopathological features in metastatic rectal vs colon cancer. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (oral presentation).

Kuo J, Malik L, Mejia A, Yip D. Compliance with international guidelines and readability of informed consent forms for cancer clinical trials. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Sardjono C, Bower J, McCloud P, Mainwaring P, Sewak S, Wong S, Kotasek D, Lee SH, Chung JS, Sanmugarajah J, Troon S, Yip D, Singh N, Crump D, De Souza P.
A Phase II study of sequential therapy with pazopanib followed by everolimus in metastatic renal cell cancer – Study Update. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Wong H, Field K, Lomax A, Tacey M, Shapiro J, McKendrick J, Zimet A, D Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Impact of tumour site on bevacizumab efficacy in metastatic colorectal cancer (mCRC). Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (oral presentation).

Kanjanapan Y, Yip D, Dahlstrom J, Craft P. Benefit of adjuvant trastuzumab with chemotherapy (ATWC) in T1N0 HER2 positive breast cancer- interim results. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Au L, Turner N, Wong H, Field K, Harold M, Boadle D, Cooray P, Karikios D, Kosmider S, Lipton L, Nott L, Parente P, Tie J, Tran B, Wong R, Yip D, Shapiro J, P Gibbs. How accurate are medical oncologists’ impressions of the management of patients with metastatic colorectal cancer (mCRC) in Australia? Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Turner N. Wong HL, Field KM, Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Lipton LR, Stefanou G, Tie J, Kosmider S, Parente P, Wong R, Lim L, Cooray P, Tran B, Desai J, Gibbs P. Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Kanjanapan Y, Yip D, Dahlstrom J, Craft P. Benefit of adjuvant trastuzumab with chemotherapy (ATWC) in T1N0 HER2 positive breast cancer- interim results. Canberra Health Annual Research Meeting, Canberra 2014 (oral presentation).

Kanjanapan Y, Dai D, Kwan E, Lawrentschuk N, Andrews M, Davis I, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P, Tran B, Yip D. Sunitinib therapy for metastatic renal cell carcinoma (mRCC) in elderly patients (age 70 and over): a multi-institutional Australian experience. Canberra Health Annual Research Meeting, Canberra 2014 (poster presentation)

Kuo J, Malik L, Mejia A, Yip D. Compliance with international guidelines and readability of informed consent forms for cancer clinical trials. Canberra Health Annual Research Meeting, Canberra 2014 (poster presentation).

Turner NH, Wong HL, Lee M, Aung SY, Rai R, Nott L, Yip D, Field K ,Shapiro J, Kosmider S, Wong R, Lipton L, Power J, Zimet A, Gibbs P. Association between diabetes mellitus (DM) and clinical outcomes in patients with metastatic colorectal cancer (mCRC). Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane, 2014 (poster presentation).

Tie J, Kinde I, Wang Y, Wong HL, Skinner I, Wong R, Steel M, Diaz LA, Papadopoulos N, Kosmider S, Yip D, Underhill C, Haydon AM, Christie M, Strausberg R, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Aung SY, Turner N, Wong HL, Maddison C, Lee M, Rai R, Yip D, Field L, Shapiro J, Tie J, Tran B, McKendrick J, Richardson G, Desai J, Gibbs P, Nott L. Clinical Presentation, Treatment, and Outcomes of Colorectal Cancer Patients with Isolated Distant Lymph Node Metastases in Australia. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Turner N, Wong HL, Field L, Wong R, Shapiro J, Yip D, Nott L, Tie J, Kosmider S, Tran B, Desai J, McKendrick J, Zimet A, Richardson G, Iddawela M, Gibbs P. Defining and measuring variation in quality of care delivered to patient with metastatic colorectal cancer in routine practice. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Au L, Turner N, Wong HL, Field K, Harold M, Boadle D, Cooray P, Karikios D, Kosmider S, Lipton L, Nott L, Parente P, Tie J, Tran B, Wong R, Yip D, Shapiro J, Gibbs P. How accurate are medical oncologists’ impressions of the management of patients with metastatic colorectal cancer (mCRC) in Australia? Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Lee M, Wong HL, Turner N, Aung SY, Rai R, Maddison C, Nott L, Yip D, Field K, Shapiro J, Tie J, Tran B, McKendrick, Ananda S, Stefenou G, Jennens R, Gibbs P. Presentation, treatment and outcomes of young patients with metastatic colorectal cancer in Australia. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Lomax A, Wong HL, Field K, Harold M, Shapiro J, McKendrick J, Zimmet A, Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Gibbs P. Prognostic impact of clinicopathological features in metastatic rectal vs colon cancer. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Wong H, Field K, Lomax A, Tacey M, Shapiro J, McKendrick J, Zimet A, D Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Impact of tumour site on bevacizumab efficacy in metastatic colorectal cancer (mCRC). European Society of Medical Oncology Congress, Madrid 2014 (abstract 7170)(poster presentation).